AKT1 and neoplasm: As the disease progresses from androgen-dependent to castrate-resistant, a decrease in both MST1 and PTEN tumor suppressor levels enhances AKT1 activity, thus linking MST1 loss with the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathway activity in driving disease progression [26,54].